The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Field
Chronicles of a small businessman who dreams of reenchanting France – Episode 36
This week in Beaujolais, Territoires d’Industrie and Indulo brought 300+ students into workshops and factory visits, turning curiosity into career sparks. Hands-on encounters with tech, makers and mentors, fuel for the next generation. Industry isn’t a relic; it’s a...
Meet us facing the ocean, Stand 028
Meet us facing the ocean, Stand 028 We are delighted to welcome you for this first day of meetings and exchanges as part of the 36ᵉ A3P Congress - dedicated to sterile production and the optimisation of quality processes according to ICH Q10. Come and see us to:...